Issues
-
Cover Image
Cover Image
Mesenchymal carcinoma cells recruit immunosuppressive Tregs and M2 macrophages to the tumor microenvironment relative to their epithelial counterparts, which recruit cytotoxic CD8+ T cells instead. In carcinomas that are comprised of heterogeneous mixtures of both epithelial and mesenchymal cells, minority subpopulations of immunosuppressive mesenchymal carcinoma cells are able to protect the entire tumor, including its epithelial cells, from immune attack. Immunofluorescence analysis of mixed tumor sections revealed that mesenchymal (green) and epithelial (white) carcinoma cells segregate to distinct sectors of the tumor. F480+ macrophages (red) are interspersed only among the mesenchymal cells of the tumor, while only a few scattered macrophages are found at the periphery of epithelial sectors within the same tumor. For details, see article by Dongre and colleagues on page 3982. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Review
Priority Report
Molecular and Cellular Pathobiology
IGFBP7 Deletion Promotes Hepatocellular Carcinoma
Tumor and Stem Cell Biology
Comprehensive Evaluation of Protein Coding Mononucleotide Microsatellites in Microsatellite-Unstable Colorectal Cancer
Therapeutics, Targets, and Chemical Biology
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity
Microenvironment and Immunology
Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer
Integrated Systems and Technologies
3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy
Prevention and Epidemiology
Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.